Literature DB >> 34819270

Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA.

Klara Martinsson1, Kerstin Dürholz2,3, Georg Schett2,3, Mario M Zaiss4,3, Alf Kastbom1.   

Abstract

Entities:  

Keywords:  arthritis; inflammation; rheumatoid; therapeutics

Mesh:

Substances:

Year:  2021        PMID: 34819270      PMCID: PMC8862054          DOI: 10.1136/annrheumdis-2021-221386

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
Transition from the autoimmune to the clinical phase of rheumatoid arthritis (RA) is a critical step that is yet insufficiently understood. Identification of factors that facilitate the progression from this prodromal RA at-risk state to clinical RA may open new possibilities for preventive interventions. In this context, nutritional factors may be critical. Short-chain fatty acids (SCFAs) are intestinal microbial metabolites that result from nutritional fibre digestion and exert immune regulatory properties.1 SCFAs have shown to effectively inhibit the onset of experimental arthritis.2 Furthermore, serum butyrate levels decrease shortly before the onset of arthritis.2 Whether SCFA levels may play a role in the transition from the autoimmune to the clinical phase of RA in humans, however, has not been studied to date. To address this concept, we measured serum SCFA levels in a prospective cohort of 82 individuals with an increased risk to develop RA.3 At inclusion, these individuals were positive for anti-citrullinated protein antibodies (ACPA) and had musculoskeletal pain but no clinical signs of arthritis (joint swelling). Baseline characteristics are shown in online supplemental table 1. Following a median follow-up of 72 months, 39 patients (48%) had developed clinical arthritis after a median of 6 months. Baseline serum samples were analysed for SCFA concentrations as previously described.4 At-risk individuals not progressing to arthritis had significantly higher mean baseline serum levels of total SCFA (ie, the sum of acetate, butyrate, propionate or pentanoate), butyrate and acetate as compared by t-test to individuals who progressed to arthritis (figure 1). In contrast, levels of propionate and pentanoate did not significantly differ (figure 1). Univariable Cox regression analyses revealed significant association between lower total SCFA levels and progression to arthritis (p=0.029), while for the individual SCFA, we found significant associations concerning butyrate (p=0.038) and acetate (p=0.039) levels, but not regarding pentanoate or propionate (online supplemental table 2). Statistical significance remained after adjusting for age, sex, symptom duration, rheumatoid factor status, ACPA levels and CRP levels (total SCFA p=0.030; butyrate p=0.009 and acetate p=0.045, online supplemental table 2).
Figure 1

Baseline serum samples from rheumatoid arthritis at-risk individuals (ACPA+; musculoskeletal pain+) progressing (n=39) or not progressing (n=43) to arthritis in a prospective observational cohort study3 were analysed for (A) acetate, (B) butyrate, (C) pentanoate and (D) propionate levels. Bars represent means and error bars represent SD. ACPA, anti-citrullinated protein antibodies.

Baseline serum samples from rheumatoid arthritis at-risk individuals (ACPA+; musculoskeletal pain+) progressing (n=39) or not progressing (n=43) to arthritis in a prospective observational cohort study3 were analysed for (A) acetate, (B) butyrate, (C) pentanoate and (D) propionate levels. Bars represent means and error bars represent SD. ACPA, anti-citrullinated protein antibodies. Butyrate levels inversely correlated with serum IgA-ACPA levels (r=−0.23, p=0.039), but not with IgG-ACPA or IgM-ACPA. No other SCFAs were significantly correlated with any ACPA subtype. These data suggest that SCFA, in particular butyrate and acetate, influences the risk for the transition from the autoimmune to the clinical phase of RA. Although most p values would not remain significant after correction for multiple testing, the data are in line with previous findings in animal models2 and thus confirm our prespecified hypothesis. As SCFAs are produced by intestinal microbiota on fermentation of dietary fibres, our findings strengthen the concept that nutritional factors could influence the onset of RA. SCFAs are critical for the barrier function of the intestinal epithelium and thereby influences the migration of cells from the gut to the joints.2 Increasing SCFA levels by direct supplementation, fiber-rich diet or faecal transplantation to restore early dysbiosis thus represent potential strategies to inhibit the onset of arthritis.4–6 In this context, high-fibre diet has already shown to increase SCFA levels and decrease inflammatory burden in patients with established RA4 but has not been applied in a preventive setting. These data suggest that a state of high SCFA concentrations, which can be reached by dietary interventions such as high-fibre diet, may go along with a lower risk to progress to clinical arthritis in individuals with a high risk to develop RA.
  6 in total

1.  Autoantibodies are major predictors of arthritis development in patients with anti-citrullinated protein antibodies and musculoskeletal pain.

Authors:  E Eloff; K Martinsson; M Ziegelasch; J Cedergren; Å Reckner; T Skogh; L Karlsson; A Ärlemalm; N V Borggreven; L A Trouw; A Kastbom
Journal:  Scand J Rheumatol       Date:  2020-11-27       Impact factor: 3.641

Review 2.  The gut-joint axis in rheumatoid arthritis.

Authors:  Mario M Zaiss; Hsin-Jung Joyce Wu; Daniele Mauro; Georg Schett; Francesco Ciccia
Journal:  Nat Rev Rheumatol       Date:  2021-03-05       Impact factor: 32.286

3.  Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis.

Authors:  Magdalena B Flak; Romain A Colas; Estefanía Muñoz-Atienza; Michael A Curtis; Jesmond Dalli; Costantino Pitzalis
Journal:  JCI Insight       Date:  2019-07-11

4.  Fecal microbiota transplantation for rheumatoid arthritis: A case report.

Authors:  Jiaqi Zeng; Lihua Peng; Wei Zheng; Feng Huang; Nana Zhang; Di Wu; Yunsheng Yang
Journal:  Clin Case Rep       Date:  2020-12-23

5.  Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.

Authors:  Narges Tajik; Michael Frech; Oscar Schulz; Fabian Schälter; Sébastien Lucas; Vugar Azizov; Kerstin Dürholz; Franziska Steffen; Yasunori Omata; Andreas Rings; Marko Bertog; Aroldo Rizzo; Aida Iljazovic; Marijana Basic; Arnd Kleyer; Stephan Culemann; Gerhard Krönke; Yubin Luo; Klaus Überla; Udo S Gaipl; Benjamin Frey; Till Strowig; Kerstin Sarter; Stephan C Bischoff; Stefan Wirtz; Juan D Cañete; Francesco Ciccia; Georg Schett; Mario M Zaiss
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

6.  Dietary Short-Term Fiber Interventions in Arthritis Patients Increase Systemic SCFA Levels and Regulate Inflammation.

Authors:  Kerstin Dürholz; Jörg Hofmann; Aida Iljazovic; Julian Häger; Sébastien Lucas; Kerstin Sarter; Till Strowig; Holger Bang; Jürgen Rech; Georg Schett; Mario M Zaiss
Journal:  Nutrients       Date:  2020-10-20       Impact factor: 5.717

  6 in total
  2 in total

Review 1.  Regulation of CD4+ and CD8+ T Cell Biology by Short-Chain Fatty Acids and Its Relevance for Autoimmune Pathology.

Authors:  Carmen Schiweck; Sharmili Edwin Thanarajah; Mareike Aichholzer; Silke Matura; Andreas Reif; Elske Vrieze; Andreas Weigert; Alexander Visekruna
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

2.  Editorial: The microbial modulation of autoimmune processes and proinflammatory pathways.

Authors:  Elias A Rahal; Margret Shirinian; Daniele Dessì
Journal:  Front Cell Infect Microbiol       Date:  2022-08-02       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.